Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma

Author： Xu Zi-Zhen   Wang Wen-Fang   Fu Wan-Bin   Wang Ai-Hua   Liu Zhi-Yin   Chen Li-Yun   Guo Pei   Li Jun-Min  

Publisher： Informa Healthcare

ISSN： 1042-8194

Source： Leukemia and Lymphoma, Vol.55, Iss.5, 2014-05, pp. : 1151-1157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

By Macaskill E.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 725-734

Springer Publishing Company

Access to resources Recommend Favorite

Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy

By                          

Experimental and Therapeutic Medicine, Vol. 6, Iss. 1, 2013-01 ,pp. : 109-114

Spandidos Publications

Access to resources Recommend Favorite

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP

By Mitrović Zdravko  

Pathology & Oncology Research, Vol. 17, Iss. 2, 2011-06 ,pp. : 243-247

Springer Publishing Company

Access to resources Recommend Favorite

Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab

By                          

Oncology Letters, Vol. 4, Iss. 3, 2012-01 ,pp. : 541-545

Spandidos Publications

Access to resources Recommend Favorite

Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP

By                                    

Experimental and Therapeutic Medicine, Vol. 3, Iss. 2, 2012-01 ,pp. : 304-308

Spandidos Publications

Access to resources Recommend Favorite